Hair Loss Medication UK: 2026 Guide

Hair loss medication UK comes down to three drugs with meaningful evidence: finasteride, minoxidil, and dutasteride. The NHS does not routinely fund any of them for androgenetic alopecia (it's classed as cosmetic), so most UK patients pay £14–£30 per month through online direct-to-consumer providers. In April 2024 the MHRA mandated a Patient Alert Card inside every finasteride pack warning of psychiatric and persistent sexual side effects — a UK-specific change that all UK patients should know about before starting.

Important: this is not medical advice

This guide is for information and reference. It is not a substitute for advice from a qualified clinician registered with the GMC or your prescribing doctor. Hair-loss medications interact with other medications and conditions, and the right regimen for you depends on your medical history. Speak to your GP or a specialist before starting, stopping, or changing any prescription. The MHRA Patient Alert Card supplied with every UK finasteride pack should be read in full before commencing treatment.

The three drugs that work

Three medications have meaningful evidence for treating androgenetic alopecia (male and female pattern hair loss): finasteride, minoxidil, and dutasteride. A fourth — ketoconazole 2% shampoo — has thinner evidence as an adjunct.

Finasteride 1mg

Efficacy

The pivotal Merck trials (Kaufman et al., 1998) tracked 1,553 men. At 12 months, 83% of men on finasteride maintained or increased hair count versus 28% on placebo. At 24 months, treated men had a net gain of 107 hairs in a 1-inch circle versus continued loss in placebo.

Mella et al's 2010 meta-analysis (Archives of Dermatology) found a mean 9.3% hair-count increase versus placebo at 12 months. The 2016 Cochrane systematic review (Adil et al.) confirmed superiority on hair count and patient-rated improvement, RR 1.82. The British Association of Dermatologists and the European Academy of Dermatology both list finasteride as first-line for male androgenetic alopecia (Grade A evidence).

Side-effect profile and the UK regulatory position

The original Merck registration trials reported sexual dysfunction in 1.8% of finasteride users versus 1.3% on placebo — an absolute difference of 0.5%. The contested question, debated in the medical literature for two decades, is whether a small subset of users experience persistent side effects after stopping the drug.

What's documented:

• Irwig (2012) — J Sex Med: 71 men with persistent sexual side effects, mean duration ~40 months post-cessation
• Wessells / Kiguradze (2016/2017) — large EHR cohort studies finding no statistically significant increase in persistent sexual dysfunction in 5ARI-exposed men versus matched controls
• Trueb (2018) — Skin Appendage Disord: notes that PFS biological mechanisms are debated, while psychological burden and nocebo effect are real
• Pathak et al (2024) — Int J Mol Sci: most recent systematic review, finds a "syndromic" presentation of neuropsychiatric symptoms (anxiety, depression) in susceptible individuals with no clear causative biomarker established

The UK regulator's position changed in April 2024: the MHRA mandated a Patient Alert Card inside every finasteride pack warning of potential psychiatric effects (depression, suicidal thoughts) and persistent sexual side effects. The MHRA action was preceded by a 2020 UK Coroner's Regulation 28 report in the inquest of James McCready, which explicitly linked finasteride use to suicidal ideation.

This is important context if you're considering finasteride: the standard Merck side-effect rates are part of the picture, but the UK regulator now requires explicit warning of more serious potential effects, and patients should make an informed decision in conversation with their prescriber.

NHS and access

Finasteride for androgenetic alopecia is not routinely funded by the NHS — it is classed as cosmetic per ICB guidance including BNSSG ICB Remedy Guidelines 2026.

UK access routes (April 2026):

None currently require a video consultation as standard.

Minoxidil

Topical

Olsen et al's 2002 J Am Acad Dermatol study established 5% as more effective than 2% (p < 0.05), with a mean 18.6% hair-count increase over 12 months. Side-effects: pruritus and contact dermatitis in ~6% of users; minimal systemic absorption when used topically as directed.

Available over the counter in the UK without prescription (Regaine and equivalents).

Oral low-dose

Sinclair's 2023/2025 work (Frontiers in Pharmacology) on oral minoxidil 2.5mg once daily reports "excellent" or "good" results in over 70% of patients at 12 months — often surpassing topical results due to better compliance and higher follicular sulphotransferase activity.

UK regulatory position: the MHRA has not licensed oral minoxidil for hair loss. Oral minoxidil is licensed only for hypertension at 5mg and above. Prescribing for hair loss is therefore strictly off-label. Some UK private prescribers will issue oral minoxidil for hair loss after a written or video consultation; standard NHS GPs typically will not.

Side effects of low-dose oral minoxidil per Sinclair:

• Hypertrichosis (unwanted body and facial hair): ~71%, but only ~5% discontinue
• Postural hypotension: under 2%
• Pedal oedema (foot/ankle swelling): under 2%

The hypertrichosis rate is high but tolerable for most patients; it can be managed with depilation.

Dutasteride

Olsen et al's 2006 J Am Acad Dermatol trial showed 0.5mg dutasteride is significantly more effective than 5mg finasteride at 12 and 24 weeks. Sexual side-effect rates are slightly higher (3–4%) but long-term safety is comparable.

UK regulatory position: dutasteride is licensed for benign prostatic hyperplasia in the UK, not for hair loss. Off-label prescribing for hair loss happens in private practice but is less common than finasteride. Some patients escalate from finasteride to dutasteride if finasteride alone is insufficient.

Around a hair transplant

The standard ISHRS Standard of Care 2024 protocol:

Continuing finasteride through surgery reduces shock loss of native hair around the recipient area. Stopping minoxidil briefly pre-op reduces intra-operative bleeding.

Most surgeons require a documented medication conversation (and ideally a current prescription) before booking surgery, particularly for younger patients with progressive native loss.

Combined regimens

The evidence supports combinations:

• Finasteride + topical minoxidil is more effective than either alone (Khandpur 2002, p < 0.01). This is the most widely used UK regimen.
• Adding ketoconazole 2% shampoo has modest evidence for additional benefit via anti-androgen and anti-inflammatory pathways (Pierard-Franchimont).
• Adding oral minoxidil to finasteride+topical is a separate conversation, weighing efficacy against the off-label prescribing route.
• Switching finasteride to dutasteride is a step-up option for non-responders, also off-label.

What you should not do

• Don't start any of these without a medical conversation. UK finasteride packs now contain a Patient Alert Card for a reason. Read it.
• Don't stop suddenly without telling your prescriber. Most short-term side effects resolve within weeks, but the conversation matters.
• Don't trust a clinic that recommends starting medication without taking a medical history. A reputable UK provider asks questions before prescribing.
• Don't expect any of these to grow back hair you've already lost permanently. They protect what you have and partially reverse early miniaturisation. Surgical restoration is the only route to genuinely refilling lost ground.

Where to start

• See our hair transplant aftercare guide for peri-procedural medication timing
• Read Recovery Timeline for what happens in the months around surgery
• Browse UK clinics that handle medication-managed cases on Graftwise

References

The evidence base for this guide is summarised below. This is an information page; clinical decisions require a qualified clinician.

1. Mella JM et al. Arch Dermatol 2010;146(10):1141-50. DOI: 10.1001/archdermatol.2010.256.
2. Kaufman KD et al. J Am Acad Dermatol 1998;39(4 Pt 1):578-89.
3. Adil A et al. Cochrane Database Syst Rev 2016 (NMA update 2020).
4. Kanti V et al. JEADV 2018;32(1):11-22 (BAD/EADV androgenetic alopecia guidance).
5. Irwig MS. J Sex Med 2012;9(11):2927-32.
6. Trueb RM et al. Skin Appendage Disord 2018.
7. Wessells H et al. J Urol 2016;195(4); Kiguradze T et al. PeerJ 2017.
8. Pathak et al. Int J Mol Sci 2024 (PFS systematic review).
9. MHRA Drug Safety Update, April 2024: "Finasteride: reminder of psychiatric and sexual side effects."
10. BNSSG ICB Remedy Guidelines: Alopecia 2026.
11. Coroner's Regulation 28 Report, Inquest of James McCready, 2020.
12. Olsen EA et al. J Am Acad Dermatol 2002;47(3):377-85 (minoxidil topical).
13. Sinclair R et al. Frontiers in Pharmacology 2025 (oral minoxidil).
14. Olsen EA et al. J Am Acad Dermatol 2006;55(6):1014-23 (dutasteride).
15. Khandpur S et al. J Dermatol 2002;29(8):489-98 (combined therapy).
16. ISHRS Standard of Care Guidelines 2024.

This article is pending review by a UK GMC-registered dermatologist or trichologist. The evidence summary above reflects publicly available peer-reviewed literature and UK regulatory positions as of April 2026.